Application of nanoparticles capable of forming spine array structure in preparation of medicine for repairing skin wound and pharmaceutical composition
By forming nanoparticles with spike array structures on the surface of skin wounds, the problem of difficult-to-treat bacterial infections is solved, long-term antibacterial and wound healing is achieved, slowing down the inflammatory response, and is better than traditional antibiotics.
Patent Information
- Application Number
- CN202411254327.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-12-06
AI Technical Summary
The prior art is difficult to effectively treat skin wound infections caused by bacterial infections, especially due to poor permeability of drugs penetrating the stratum corneum and the inability to release for a long time, and traditional hydrogels are difficult to solve the generation of drug-resistant bacteria.
A nanoparticle capable of forming a spike array structure was developed, composed of gold cores and nano-grain, and prepared by a one-pot method. The nanoparticles form spike structures on the surface of the skin wound, physically pierce bacteria, directly kill bacteria, and Apply to wounds by spray or gel dosage form.
It achieves long-acting antibacterial effects, avoids the production of drug-resistant bacteria, promotes wound healing and collagen deposition, slows down inflammatory responses, and is better than the effect of traditional antibiotics on methicillin-resistant Staphylococcus aureus.
Smart Images

Figure CN119074691A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of nano-medicine, and specifically relates to the application of nano-particles capable of forming a spike array structure in the preparation of a medicine for repairing skin wounds and a medicine composition. Background Art
[0002] Bacteria are closely related to human survival and social development today. Since Pasteur proved in the 19th century that almost every organism, object and environment is full of bacteria, people's research on bacteria has reached a new height. However, the threat of bacterial infection to human health, especially drug-resistant strains, has been recognized as one of the top ten public health threats in the world. About half a century ago, the medical community believed that with the improvement of hygiene and nutrition conditions and the development of drugs and vaccines, the mortality rate caused by bacterial infectious diseases would steadily decline and gradually become insignificant. However, in recent years, the mortality rate caused by bacterial infections has not declined as expected. According to the latest data given by the World Health Organization (WHO), bacterial infections are the second leading cause of death in the world, second only to ischemic heart disease, accounting for one-eighth of the global deaths. Among them, the production of drug-resistant bacteria caused by excessive use of disinfectants and antibiotics has increased the difficulty of treating bacterial infections, which is also one of the main reasons for the huge harm of bacterial infections.
[0003] Skin and soft tissue infections caused by bacteria, fungi and viruses are one of the most common infections in the world. Damaged skin is easily infected by external bacteria due to its wound exposure. At the same time, a large amount of tissue fluid will seep out, causing wound suppuration, inflammation and infection, which increases the difficulty of wound healing. In order to ensure rapid and healthy wound healing, wound hemostasis and post-injury treatment of biomaterial dressings are particularly important. At this time, it is necessary to compound antibacterial materials and hydrogels. The excellent mechanical properties of hydrogel materials enable hydrogel composite antibacterial materials to add a layer of physical barrier on the surface of damaged skin, and its air permeability and water absorption can well solve the problem of tissue fluid exudation, accelerate wound skin healing, and thus treat skin damage bacterial infection. However, because the drug has poor permeability through the stratum corneum, the drug bioavailability at the infected site is low, and it cannot be released for a long time, it is difficult to treat skin infections caused by bacteria with traditional hydrogels.
[0004] Regular sharp array structures on the surface of natural structures can physically puncture bacteria to destroy the bacterial structure, or even directly kill bacteria to achieve long-term antibacterial effect and avoid the production of drug-resistant bacteria induced by repeated medication. However, most of the surfaces or materials with spike structure arrays are currently prepared by high-energy consumption methods such as ion etching, 3D printing, and template preparation, and the preparation conditions are harsh and complex, making it difficult to obtain practical applications in daily life. At present, there is an urgent need for a skin wound repair nanomedicine that can produce spike arrays and can be synthesized in an environmentally friendly manner and easily applied. Summary of the invention
[0005] In view of the shortcomings of the prior art, the purpose of the present invention is to provide an application of nanoparticles that can form a spike array structure in the preparation of a skin wound repair drug and a pharmaceutical composition. The present invention innovatively develops a skin wound repair nanomedicine that can produce a spike array and can be synthesized in an environmentally friendly and simple manner, providing a novel and effective solution for skin wound repair.
[0006] To achieve the above object, the present invention is implemented by the following technical solutions:
[0007] The present invention provides an application of nanoparticles capable of forming a spike array structure in preparing a drug for repairing skin wounds. The nanoparticles are composed of a gold core and nanoparticles distributed on the surface of the gold core. The nanoparticles can form a spike array structure on the surface of the skin wound for repairing the skin wound.
[0008] As a further optimization scheme of the present invention, the nanoparticles are applied to skin wounds to fight infection.
[0009] As a further optimization scheme of the present invention, the nanoparticles are used to promote skin wound healing.
[0010] As a further optimization scheme of the present invention, the nanoparticles are used to promote collagen deposition in skin wounds.
[0011] As a further optimization scheme of the present invention, the nanoparticles are used to inhibit inflammatory responses caused by skin wound infections.
[0012] As a further optimization scheme of the present invention, the particle size of the gold core is 15-25 nm, the length of the nanoparticle is 85-95 nm, and the nanoparticle is composed of metal oxide, preferably ZnO.
[0013] As a further optimization scheme of the present invention, the preparation method of the nanoparticles includes: weighing anhydrous zinc acetate powder, tetrahydrate chloroauric acid powder, triphenyl phosphate and oleylamine according to the designed ratio of 1: (4-8): (10-15): (4-6), mixing, reacting in an oil bath at 130-160° C. for 4-6 hours, and then reacting at 190-220° C. for 4-6 hours to obtain a nanoparticle solution, and purifying and drying to obtain solid powder nanoparticles.
[0014] As a further optimization scheme of the present invention, the step of purifying and drying the nanoparticle solution includes: adding 4-6 times the volume of isopropanol to the nanoparticle solution, mixing thoroughly and then centrifuging to separate the phases, discarding the upper clear layer, dissolving the lower precipitate with chloroform, then evaporating the solution to dryness, dispersing with isopropanol and centrifuging and precipitating, repeating multiple times, and finally dissolving the precipitated product in tert-butanol, freezing with liquid nitrogen and vacuum drying to obtain a solid powder product.
[0015] The present invention also provides a pharmaceutical composition for repairing skin wounds, which comprises the nanoparticles used in the application and a pharmaceutically acceptable auxiliary agent.
[0016] As a further optimization scheme of the present invention, the dosage form of the pharmaceutical composition includes a spray, and the preparation method of the spray includes: dissolving the nanoparticles in a mixed solvent of ultrapure water and ethanol in a volume ratio of 1:(5-10), and ultrasonicating for 5-10 minutes to obtain the spray.
[0017] As a further optimization scheme of the present invention, the dosage form of the pharmaceutical composition includes a gel, and the preparation method of the gel includes: dissolving carbomer powder in ultrapure water to prepare a mixed solution of 0.05-0.15 g / mL, and stirring overnight; then using 0.01-0.05 mol / L hydrochloric acid to adjust the pH to 2-5, and then adding 40-50 mg of nanoparticles, stirring thoroughly and standing to defoam to obtain a gel.
[0018] Compared with the prior art, the present invention has the following beneficial effects:
[0019] (1) The present invention is the first to prepare a nanoparticle having a three-dimensional spike structure and capable of forming a spike array through a one-pot method. The prepared nanoparticles are uniform in size, with a gold core particle size of 15-25nm and a nanostructure length of 85-95nm. The nanoparticles can form a spike array structure on the surface of skin wounds, which can physically puncture bacteria to destroy the bacterial structure or even directly kill the bacteria, thereby achieving long-term antibacterial effect and avoiding the production of drug-resistant bacteria induced by multiple medications, thereby providing a novel and effective solution for skin wound anti-infection.
[0020] (2) The nanoparticles prepared by the present invention can be uniformly and stably dispersed in ethanol, and can be directly and simply sprayed using a spray bottle, or made into a gel and can be used in a rat skin wound infection model of methicillin-resistant Staphylococcus aureus with good antibacterial effect, which is better than vancomycin, a senior antibiotic currently used clinically for methicillin-resistant Staphylococcus aureus. At the same time, it can promote wound healing, collagen deposition, and reduce the inflammatory response caused by wound infection. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1Schematic diagram of the synthesis process of bionic Au@ZnO nanoparticles according to Example 1 of the present invention.
[0022] Figure 2 This is a transmission electron microscope image of the bionic Au@ZnO nanoparticles of Example 1 of the present invention.
[0023] Figure 3 This is a transmission electron microscope image of the bionic Au@ZnO nanoparticles of Example 1 of the present invention.
[0024] Figure 4 This is a high-resolution transmission electron microscope image of the bionic Au@ZnO nanoparticles of Example 1 of the present invention.
[0025] Figure 5 This is a high-angle annular dark-field image of the bionic Au@ZnO nanoparticles of Invention Example 1.
[0026] Figure 6 for Figure 5 EDS mapping image of gold elements.
[0027] Figure 7 for Figure 5 EDS mapping image of zinc element.
[0028] Figure 8 for Figure 5 EDS mapping image of oxygen element.
[0029] Fig. 9 Scanning electron microscope images of the spray and gel containing biomimetic Au@ZnO nanoparticles of Inventive Example 1.
[0030] Fig.10 Scanning electron microscope images of gauze before and after being coated with the spray and gel containing biomimetic Au@ZnO nanoparticles in Example 1 of the invention.
[0031] Fig.11 Graphs showing the recovery of rat wounds without infection, wounds infected with methicillin-resistant Staphylococcus aureus treated with normal saline, wounds infected with methicillin-resistant Staphylococcus aureus treated with vancomycin, and wounds treated with the biomimetic Au@ZnO nanoparticle gel according to Example 1 of the invention.
[0032] Fig.12 Statistical graphs of the recovery of rat wounds without infection, wounds infected with methicillin-resistant Staphylococcus aureus treated with normal saline, wounds infected with methicillin-resistant Staphylococcus aureus treated with vancomycin, and wounds treated with the biomimetic Au@ZnO nanoparticle gel according to Example 1 of the invention.
[0033] Fig.13These are graphs showing bacterial plating from rats' uninfected wounds, wounds infected with methicillin-resistant Staphylococcus aureus treated with normal saline, wounds infected with methicillin-resistant Staphylococcus aureus treated with vancomycin, and wounds treated with the bionic Au@ZnO nanoparticle gel according to Example 1 of the invention.
[0034] Fig.14 Statistical graphs of bacterial counts in rat wounds without infection, wounds infected with methicillin-resistant Staphylococcus aureus treated with normal saline, wounds infected with methicillin-resistant Staphylococcus aureus treated with vancomycin, and wounds treated with the biomimetic Au@ZnO nanoparticle gel according to Example 1 of the invention.
[0035] Fig.15 The wound healing width and statistical graphs of rats with uninfected wounds, wounds infected with methicillin-resistant Staphylococcus aureus treated with normal saline, wounds infected with methicillin-resistant Staphylococcus aureus treated with vancomycin, and wounds treated with the biomimetic Au@ZnO nanoparticle gel according to Example 1 of the invention.
[0036] Fig.16 The collagen recovery and statistical graphs of rat wounds without infection, wounds infected with methicillin-resistant Staphylococcus aureus treated with normal saline, wounds infected with methicillin-resistant Staphylococcus aureus treated with vancomycin, and wounds treated with the biomimetic Au@ZnO nanoparticle gel according to Example 1 of the invention.
[0037] Fig.17 Gram staining and statistical graphs of rat wounds without infection, wounds infected with methicillin-resistant Staphylococcus aureus treated with normal saline, wounds infected with methicillin-resistant Staphylococcus aureus treated with vancomycin, and wounds treated with the biomimetic Au@ZnO nanoparticle gel of Example 1.
[0038] Fig.18 The inflammatory indicator IL-6 staining and statistical graphs of rats with uninfected wounds, wounds infected with methicillin-resistant Staphylococcus aureus treated with normal saline, wounds infected with methicillin-resistant Staphylococcus aureus treated with vancomycin, and wounds treated with the biomimetic Au@ZnO nanoparticle gel according to Example 1 of the invention.
[0039] Fig.19 The inflammatory indicator IL-1β staining and statistical graphs of rats with uninfected wounds, wounds infected with methicillin-resistant Staphylococcus aureus treated with normal saline, wounds infected with methicillin-resistant Staphylococcus aureus treated with vancomycin, and wounds treated with the biomimetic Au@ZnO nanoparticle gel according to Example 1 of the invention.
[0040] Fig. 20The inflammatory indicator TNF-α staining and statistical graphs of rats with uninfected wounds, wounds infected with methicillin-resistant Staphylococcus aureus treated with normal saline, wounds infected with methicillin-resistant Staphylococcus aureus treated with vancomycin, and wounds treated with the biomimetic Au@ZnO nanoparticle gel according to Example 1 of the invention. DETAILED DESCRIPTION
[0041] In order to enable those skilled in the art to better understand the technical solution of the present invention, the preferred implementation scheme of the present invention is described below in conjunction with specific embodiments, but it should not be understood as limiting the present invention and is only used as an example.
[0042] Embodiment 1:
[0043] Preparation process Figure 1 As shown, anhydrous zinc acetate powder, tetrahydrate chloroauric acid powder, triphenyl phosphate and oleylamine are weighed and mixed according to the designed ratio of 1:6:12:5, reacted in an oil bath at 145°C for 5 hours, and then reacted at 200°C for 5 hours to obtain a nanoparticle solution, 5 volumes of isopropanol are added to the nanoparticle solution, and the mixture is fully mixed and then centrifuged at high speed to separate the phases, the upper clear layer is discarded, the lower precipitate is dissolved with chloroform, and then the solution is evaporated to dryness, dispersed with isopropanol and centrifuged and precipitated, which is repeated many times, and finally the precipitated product is dissolved in tert-butanol, frozen with liquid nitrogen and dried in vacuo to obtain a solid powder product, and then the solid powder nanoparticles are obtained after purification and drying.
[0044] Figure 2 FIG. 1 is a transmission electron microscope image of the biomimetic Au@ZnO nanoparticles of Example 1 of the present invention. Figure 2 It can be seen that the size of Au@ZnO nanoparticles is about 200nm, of which the gold core particle size is 20-25nm and the length of zinc oxide nanoparticles is 90-110nm.
[0045] Figure 3 FIG. 1 is a transmission electron microscope image of the biomimetic Au@ZnO nanoparticles of Example 1 of the present invention. Figure 3 The morphology of Au@ZnO nanoparticles can be seen in the figure.
[0046] Figure 4 This is a high-resolution transmission electron microscope image of the biomimetic Au@ZnO nanoparticles of Example 1 of the present invention. Figure 4 It can be seen that the interplanar spacing of the gold core of Au@ZnO nanoparticles is and Corresponding to the (111) and (200) planes of Au, the interplanar spacing in ZnO nanorods is Corresponding to the (100) crystal plane of ZnO.
[0047] Figure 5This is a high-angle annular dark field image of the biomimetic Au@ZnO nanoparticles of Invention Example 1. Figure 5 The morphology of Au@ZnO nanoparticles can be seen in the figure.
[0048] Figure 6 for Figure 5 EDS mapping image of gold element. Figure 5 From the distribution of gold elements, it can be seen that the core of the nano-bionic sea urchin nanoparticles is a gold core.
[0049] Figure 7 for Figure 5 EDS mapping image of zinc element. Figure 5 From the distribution of zinc element, it can be seen that the periphery of the nano-bionic sea urchin nanoparticles contains zinc element.
[0050] Figure 8 for Figure 5 EDS mapping image of oxygen element. Figure 5 From the distribution of oxygen elements, it can be seen that the three-dimensional nanorod structure of nano-bionic sea urchin nanoparticles is composed of zinc oxide.
[0051] Embodiment 2:
[0052] Preparation process Figure 1 As shown, anhydrous zinc acetate powder, tetrahydrate chloroauric acid powder, triphenyl phosphate and oleylamine are weighed and mixed according to the designed ratio of 1:4:15:6, and reacted in an oil bath at 160°C for 4 hours, and then reacted at 220°C for 4 hours to obtain a nanoparticle solution, 6 volumes of isopropanol are added to the nanoparticle solution, and the mixture is fully mixed and then centrifuged at high speed to separate the phases, the upper clear layer is discarded, the lower precipitate is dissolved with chloroform, and then the solution is evaporated to dryness, dispersed with isopropanol and centrifuged and precipitated, which is repeated many times, and finally the precipitated product is dissolved in tert-butanol, frozen with liquid nitrogen and dried in vacuo to obtain a solid powder product, and then solid powder nanoparticles are obtained after purification and drying.
[0053] Embodiment 3:
[0054] Preparation process Figure 1 As shown, anhydrous zinc acetate powder, tetrahydrate chloroauric acid powder, triphenyl phosphate and oleylamine are weighed and mixed according to the designed ratio of 1:8:10:4, reacted in an oil bath at 130°C for 6 hours, and then reacted at 190°C for 6 hours to obtain a nanoparticle solution, 4 volumes of isopropanol are added to the nanoparticle solution, and the mixture is fully mixed and then centrifuged at high speed to separate the phases, the upper clear layer is discarded, the lower precipitate is dissolved with chloroform, and then the solution is evaporated to dryness, dispersed with isopropanol and centrifuged and precipitated, which is repeated many times, and finally the precipitated product is dissolved in tert-butanol, frozen with liquid nitrogen and dried in vacuo to obtain a solid powder product, and then solid powder nanoparticles are obtained after purification and drying.
[0055] Example 4
[0056] Based on the bionic Au@ZnO nanoparticles prepared in Example 1, a spray containing bionic Au@ZnO nanoparticles is prepared by the following preparation method:
[0057] The nanoparticles were dissolved in a mixed solvent of ultrapure water and ethanol in a volume ratio of 1:10, and ultrasonicated for 10 minutes to obtain a spray.
[0058] Based on the bionic Au@ZnO nanoparticles prepared in Example 1, a gel containing bionic Au@ZnO nanoparticles was prepared by the following method:
[0059] Carbomer powder was dissolved in ultrapure water to prepare a 0.15 g / mL mixed solution, and stirred overnight; 0.05 mol / L hydrochloric acid was used to adjust the pH to 5, and 50 mg of nanoparticles were added, stirred thoroughly, and allowed to stand for defoaming to obtain a gel.
[0060] Fig. 9 The scanning electron microscope images of the spray and gel containing the biomimetic Au@ZnO nanoparticles of Invention Example 1 are shown in FIG. Fig. 9 It can be seen that Au@ZnO nanoparticles sprayed or applied onto an ultra-flat gold surface can form a spiked antibacterial array similar to the surface of a cicada wing.
[0061] Fig.10 The scanning electron microscope images of the gauze before and after being coated with the spray and gel containing the biomimetic Au@ZnO nanoparticles in Example 1 of the invention. Fig.10 It can be seen that Au@ZnO nanoparticles are sprayed or applied to gauze, and a spiked antibacterial array similar to the surface of a cicada wing can be formed on the gauze fibers.
[0062] Example 5
[0063] The volume ratio of ultrapure water and ethanol in Example 4 was adjusted to 1:5, and ultrasonicated for 5 minutes to obtain a spray.
[0064] Example 6
[0065] The volume ratio of ultrapure water and ethanol in Example 4 was adjusted to 1:8, and ultrasonication was performed for 8 minutes to obtain a spray.
[0066] Example 7
[0067] Based on the bionic Au@ZnO nanoparticles prepared in Example 1, a gel containing bionic Au@ZnO nanoparticles was prepared by the following method:
[0068] Carbomer powder was dissolved in ultrapure water to prepare a mixed solution of 0.05 g / mL, and stirred overnight; the pH was adjusted to 3 using 0.01 mol / L hydrochloric acid, and 45 mg of nanoparticles were added, stirred thoroughly, and allowed to stand for defoaming to obtain a gel.
[0069] Example 8
[0070] Based on the bionic Au@ZnO nanoparticles prepared in Example 1, a gel containing bionic Au@ZnO nanoparticles was prepared by the following method:
[0071] Carbomer powder was dissolved in ultrapure water to prepare a mixed solution of 0.10 g / mL, and stirred overnight; the pH value was adjusted to 2 using 0.03 mol / L hydrochloric acid, and 40 mg of nanoparticles were added, stirred thoroughly, and allowed to stand for defoaming to obtain a gel.
[0072] Example 9
[0073] Based on the bionic Au@ZnO nanoparticle gel prepared in Example 4, the repairing effect of the bionic Au@ZnO nanoparticle gel on skin wounds was investigated.
[0074] To create the wound, mice were first anesthetized and their backs were shaved. A circular full-thickness wound was created using a skin trephine with a diameter of approximately 25 mm. Subsequently, 100 μL of MRSA suspension (10 6 CFU / mL) was used as the MRSA-infected wound for infection, and 100 μL of normal saline was injected as the shame group without MRSA infection. Subsequently, the infected mice were randomly divided into the following groups: control group (normal saline), vancomycin, Au@ZnO-NUs. Each wound was treated only once on day 0. On days 2, 4, 6, and 12, standard swab cultures were performed to confirm wound infection, followed by the solid agar plate method. The bacterial CFU on the plate was diluted 10 times and analyzed. In order to monitor the healing process of the infected wounds, wound photos were taken on days 1, 2, 4, 6, and 12. The wound healing percentage was calculated using ImageJ software and the following formula:
[0075]
[0076] After the twelfth day, the rats were euthanized, and their skin was fixed and sectioned for H&E, Masson, Gram, IL-6, IL-1β, and TNF-α staining, and the wound healing percentage, bacterial infection, and inflammation indicators were calculated using ImageJ software.
[0077] Fig.11The figure shows the wound recovery of rats with uninfected wounds, wounds infected with methicillin-resistant Staphylococcus aureus treated with normal saline, wounds infected with methicillin-resistant Staphylococcus aureus treated with vancomycin, and wounds treated with the biomimetic Au@ZnO nanoparticle gel of Example 1. As can be seen from the figure, the control group not inoculated with MRSA showed no signs of infection and the wound size was reduced. However, different reactions were observed between the groups after exposure to MRSA infection and receiving various treatments. In the MRSA-infected group treated with normal saline, obvious evidence of bacterial infection and a large amount of pus production were observed. Even on the 4th day, due to excessive accumulation of pus, persistent peripheral skin damage and infection were also obvious, resulting in impaired hair regeneration near the wound. The wounds treated with vancomycin and biomimetic Au@ZnO nanoparticle gel healed better, and the recovery of the wounds was roughly the same as that of the control group that was not inoculated with MRSA.
[0078] Fig.12 The figure shows the recovery of wounds of rats without infection, wounds infected with methicillin-resistant Staphylococcus aureus treated with normal saline, wounds infected with methicillin-resistant Staphylococcus aureus treated with vancomycin, and wounds treated with the biomimetic Au@ZnO nanoparticle gel of Invention Example 1. As can be seen from the figure, the wound closure rates of wounds treated with the biomimetic Au@ZnO nanoparticle gel on the 2nd, 4th, 6th and 12th days were only 1.94%, 10.32%, 18.94% and 66.37%, respectively, which were better than the vancomycin group and similar to the blank control group.
[0079] Fig.13 The figure shows the bacterial plating of wounds without infection, wounds infected with methicillin-resistant Staphylococcus aureus treated with normal saline, wounds infected with methicillin-resistant Staphylococcus aureus treated with vancomycin, and wounds treated with biomimetic Au@ZnO nanoparticle gel according to Example 1 of the invention. As can be seen from the figure, no bacteria were detected on the corresponding agar plates of the control group not inoculated with MRSA, indicating that there were no bacteria in the wound site, while there were bacteria in the control group inoculated with MRSA. The number of bacteria in the wounds treated with vancomycin and biomimetic Au@ZnO nanoparticle gel was less, and the group treated with biomimetic Au@ZnO nanoparticle gel was better than the vancomycin group and similar to the blank control group.
[0080] Fig.14The figure shows the number of bacteria in the wounds of rats without infection, wounds infected with methicillin-resistant Staphylococcus aureus treated with normal saline, wounds infected with methicillin-resistant Staphylococcus aureus treated with vancomycin, and wounds treated with the biomimetic Au@ZnO nanoparticle gel of Invention Example 1. As can be seen from the figure, no bacteria were detected on the corresponding agar plate of the control group not inoculated with MRSA, indicating that there were no bacteria in the wound site, while there were bacteria in the control group inoculated with MRSA. The number of bacteria in the wounds treated with vancomycin and biomimetic Au@ZnO nanoparticle gel was less, and the group treated with biomimetic Au@ZnO nanoparticle gel was better than the vancomycin group and similar to the blank control group.
[0081] Fig.15 The wound healing width and statistical graphs of rats with uninfected wounds, wounds infected with methicillin-resistant Staphylococcus aureus treated with normal saline, wounds infected with methicillin-resistant Staphylococcus aureus treated with vancomycin, and wounds treated with biomimetic Au@ZnO nanoparticle gel according to Example 1 of the invention. It can be seen from the figure that the MRSA infection group treated with biomimetic Au@ZnO nanoparticle gel showed the smallest scar width, which was only 3.18m. This is comparable to the scar width of 3.84mm in the non-MRSA infected wound control group, but significantly smaller than the 4.77mm scar width of the MRSA infection group treated with vancomycin. The scars of the group treated with biomimetic Au@ZnO nanoparticle gel and vancomycin were smaller than the 7.57mm of the MRSA infection group treated with normal saline.
[0082] Fig.16 The recovery and statistical graphs of collagen in rats with uninfected wounds, wounds infected with methicillin-resistant Staphylococcus aureus treated with normal saline, wounds infected with methicillin-resistant Staphylococcus aureus treated with vancomycin, and wounds treated with the biomimetic Au@ZnO nanoparticle gel of Invention Example 1. Masson trichrome staining showed that the collagen ratio (64.73%) after treatment with the biomimetic Au@ZnO nanoparticle gel was significantly enhanced compared with the MRSA-infected wounds treated with only normal saline (27.18%) and vancomycin (55.84%), and even exceeded the level of the non-MRSA infection group (58.53%).
[0083] Fig.17The Gram staining and statistical graph of the wounds of rats without infection, wounds infected with methicillin-resistant Staphylococcus aureus treated with normal saline, wounds infected with methicillin-resistant Staphylococcus aureus treated with vancomycin, and wounds treated with the biomimetic Au@ZnO nanoparticle gel of Invention Example 1. Gram-positive staining showed that the bacterial rate of the stained area of the MRSA-infected wounds treated with the biomimetic Au@ZnO nanoparticle gel was only 0.16%, which was significantly lower than that of the MRSA-infected wounds treated with only vancomycin (0.57%) and normal saline (1.65%), and even exceeded the level of the non-MRSA infection group (0.27%).
[0084] Fig.18 The inflammatory indicator IL-6 staining and statistical graphs of rats with uninfected wounds, wounds infected with methicillin-resistant Staphylococcus aureus treated with normal saline, wounds infected with methicillin-resistant Staphylococcus aureus treated with vancomycin, and wounds treated with the biomimetic Au@ZnO nanoparticle gel according to Example 1 of the invention.
[0085] Fig.19 The inflammatory indicator IL-1β staining and statistical graphs of rats with uninfected wounds, wounds infected with methicillin-resistant Staphylococcus aureus treated with normal saline, wounds infected with methicillin-resistant Staphylococcus aureus treated with vancomycin, and wounds treated with the biomimetic Au@ZnO nanoparticle gel according to Example 1 of the invention.
[0086] Fig. 20 The inflammatory index TNF-α staining and statistical graphs of rats with uninfected wounds, wounds infected with methicillin-resistant Staphylococcus aureus treated with normal saline, wounds infected with methicillin-resistant Staphylococcus aureus treated with vancomycin, and the biomimetic Au@ZnO nanoparticle gel treated with Example 1 of the invention. Compared with the MRSA infection group treated with vancomycin (blue column) and normal saline (red column) alone, the inflammatory factors in the MRSA infection wound group treated with biomimetic Au@ZnO nanoparticle gel (purple column) showed a significant decrease, reaching the level observed in the non-MRSA infection group (green column). These results show that Au@ZnO-NUs, compared with vancomycin, exhibits superior efficacy in improving inflammation induced by the MRSA infection model.
[0087] The above are only preferred embodiments of the present invention. It should be noted that the above preferred embodiments should not be regarded as limiting the present invention, and the protection scope of the present invention should be based on the scope defined by the claims. For ordinary technicians in this technical field, several improvements and modifications can be made without departing from the spirit and scope of the present invention, and these improvements and modifications should also be regarded as the protection scope of the present invention.
Claims
1. Use of nanoparticles capable of forming a spike array structure in the preparation of a drug for repairing skin wounds, characterized in that: The nanoparticles consist of a gold core and nanoparticles distributed on the surface of the gold core. The nanoparticles can form a spike array structure on the surface of a skin wound for repairing the skin wound.
2. The use according to claim 1, characterized in that: The nanoparticles are applied to skin wounds to fight infection.
3. The use according to claim 1, characterized in that: The nanoparticles are used to promote skin wound healing.
4. The use according to claim 1, characterized in that: The nanoparticles are used to promote collagen deposition in skin wounds.
5. The use according to claim 1, characterized in that: The nanoparticles are used to inhibit inflammatory responses caused by skin wound infection.
6. The use according to claim 1, characterized in that: The particle size of the gold core is 15-25 nm, the length of the nano-copper is 85-95 nm, and the nano-copper is composed of metal oxide.
7. The use according to claim 1, characterized in that: The preparation method of the nanoparticles comprises: weighing anhydrous zinc acetate powder, tetrahydrate chloroauric acid powder, triphenyl phosphate and oleylamine according to a designed ratio of 1: (4-8): (10-15): (4-6), mixing, reacting in an oil bath at 130-160° C. for 4-6 hours, and then reacting at 190-220° C. for 4-6 hours to obtain a nanoparticle solution, and purifying and drying to obtain solid powder nanoparticles.
8. A pharmaceutical composition for repairing skin wounds, characterized in that: The pharmaceutical composition comprises the nanoparticles used in the application according to any one of claims 1 to 6, and a pharmaceutically acceptable adjuvant.
9. The pharmaceutical composition according to claim 8, characterized in that The dosage form of the pharmaceutical composition includes a spray, and the preparation method of the spray includes: dissolving the nanoparticles in a mixed solvent with a volume ratio of ultrapure water and ethanol of 1:(5-10), and ultrasonicating for 5-10 minutes to obtain the spray.
10. The pharmaceutical composition according to claim 8, characterized in that The dosage form of the pharmaceutical composition includes a gel, and the preparation method of the gel includes: dissolving carbomer powder in ultrapure water to prepare a mixed solution of 0.05-0.15 g / mL, and stirring overnight; then using 0.01-0.05 mol / L hydrochloric acid to adjust the pH to 2-5, and then adding 40-50 mg of nanoparticles, fully stirring and standing to defoam to obtain a gel.
Citation Information
Patent Citations
Copper-containing hydrogel and application thereof in bacterial infection inhibition
CN116999386A
Bionic Au-ZnO nano sea urchin with three-dimensional spine structure as well as preparation method and application of bionic Au-ZnO nano sea urchin
CN117161395A
Cited By
Bionic pine needle nano antibacterial material as well as preparation method and application thereof
CN120208283A
A bionic pine needle nano antibacterial material and its preparation method and application
CN120208283B
